DSGN Valuation

Design Therapeutics Inc

Add to Watchlist

Advanced Chart

4.820

+0.54(12.617%)1D

Overview
Forecast
Valuation
Earnings

DSGN Relative Valuation

DSGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, DSGN is overvalued; if below, it's undervalued.

Historical Valuation

Design Therapeutics Inc (DSGN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -9.59. The fair price of Design Therapeutics Inc (DSGN) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：4.28

Fair

-3.10

Trailing

Forward

0.00

EV/EBITDA

Design Therapeutics Inc. (DSGN) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -4.62. The thresholds are as follows: Strongly Undervalued below -19.81, Undervalued between -19.81 and -12.22, Fairly Valued between 2.98 and -12.22, Overvalued between 2.98 and 10.57, and Strongly Overvalued above 10.57. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.33

EV/EBIT

Design Therapeutics Inc. (DSGN) has a current EV/EBIT of -0.33. The 5-year average EV/EBIT is -5.30. The thresholds are as follows: Strongly Undervalued below -26.06, Undervalued between -26.06 and -15.68, Fairly Valued between 5.08 and -15.68, Overvalued between 5.08 and 15.47, and Strongly Overvalued above 15.47. The current Forward EV/EBIT of -0.33 falls within the Historic Trend Line -Fairly Valued range.

0.00

Design Therapeutics Inc. (DSGN) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

0.00

P/OCF

Design Therapeutics Inc. (DSGN) has a current P/OCF of 0.00. The 5-year average P/OCF is -9.90. The thresholds are as follows: Strongly Undervalued below -36.93, Undervalued between -36.93 and -23.41, Fairly Valued between 3.62 and -23.41, Overvalued between 3.62 and 17.13, and Strongly Overvalued above 17.13. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Design Therapeutics Inc. (DSGN) has a current P/FCF of 0.00. The 5-year average P/FCF is -3.75. The thresholds are as follows: Strongly Undervalued below -18.18, Undervalued between -18.18 and -10.96, Fairly Valued between 3.47 and -10.96, Overvalued between 3.47 and 10.68, and Strongly Overvalued above 10.68. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Design Therapeutics Inc (DSGN) has a current Price-to-Book (P/B) ratio of 1.07. Compared to its 3-year average P/B ratio of 1.16 , the current P/B ratio is approximately -7.89% higher. Relative to its 5-year average P/B ratio of 1.45, the current P/B ratio is about -26.50% higher. Design Therapeutics Inc (DSGN) has a Forward Free Cash Flow (FCF) yield of approximately -21.15%. Compared to its 3-year average FCF yield of -21.95%, the current FCF yield is approximately -3.65% lower. Relative to its 5-year average FCF yield of -15.86% , the current FCF yield is about 33.40% lower.

1.14

P/B

Median3y

1.16

Median5y

1.45

0.00

FCF Yield

Median3y

-21.95

Median5y

-15.86

Competitors Valuation Multiple

The average P/S ratio for DSGN's competitors is 1.69, providing a benchmark for relative valuation. Design Therapeutics Inc Corp (DSGN) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

DSGN.O

Design Therapeutics Inc

Mereo BioPharma Group PLC

DiaMedica Therapeutics Inc

Loss

196.41M

ZYBT.O

Zhengye Biotechnology Holding Ltd

Performance Decomposition

Market capitalization of DSGN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of DSGN in the past 1 year is driven by Unknown.